Long-term follow-up of treatment-naïve HBeAg-negative patients with chronic hepatitis B

[1]  D. Bonsall,et al.  Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adults , 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  Suleyman Sayar,et al.  Diagnostic Performance of Non-invasive Fibrosis Indexes in Hepatitis B Related Fibrosis , 2020 .

[3]  Ah Ram Lee,et al.  Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. , 2019, Journal of hepatology.

[4]  D. Jun,et al.  Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis , 2018, World journal of gastroenterology.

[5]  J. Trebicka,et al.  EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.

[6]  M. Buti,et al.  Long‐term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[7]  F. Tabak,et al.  A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. , 2017, Clinics and research in hepatology and gastroenterology.

[8]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[9]  J. Park,et al.  Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients , 2017, BMC Gastroenterology.

[10]  A. Cuconati,et al.  Hepatitis B Virus , 2017, Methods in Molecular Biology.

[11]  M. Yuen,et al.  World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. , 2016, Journal of clinical gastroenterology.

[12]  F. Tacke,et al.  Treatment for hepatitis B in patients with drug resistance. , 2016, Annals of translational medicine.

[13]  G. Papatheodoridis,et al.  The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy , 2016, Clinical and molecular hepatology.

[14]  I. Hatemi,et al.  Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B. , 2016, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[15]  Min Yu,et al.  Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. , 2015, World journal of gastroenterology.

[16]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[17]  M. Buti,et al.  Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.

[18]  M. Turanli,et al.  Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[19]  M. Fincancı,et al.  Comparison of tenofovir and entecavir in patients with chronic HBV infection. , 2013, European review for medical and pharmacological sciences.

[20]  R. Fontana,et al.  Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B , 2013, Alimentary pharmacology & therapeutics.

[21]  Ronald E. Rose,et al.  Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.

[22]  M. Manns,et al.  Trial Results : Telbivudine Is Superior to Lamivudine in atients With Chronic Hepatitis B UN – , 2022 .

[23]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[24]  M. Yuen,et al.  Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease , 2007, Antiviral therapy.

[25]  G. Makar.  Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD Al463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§ , 2007 .

[26]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[27]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[28]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .